Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | G6PD | P11413 | 1/20 | 0.44 |
| ▸ | FBP1 | P09467 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8039808 | 1.00 | ALDH1A1 (0.46) | ALDH1A1NPC1MAPTG6PDFBP1 | |
| SCHEMBL28552488 | 0.81 | FBP1 (0.44) | ALDH1A1NPC1FBP1TDP1HSD17B10 | |
| SCHEMBL15216491 | 0.81 | FBP1 (0.44) | ALDH1A1NPC1FBP1TDP1HSD17B10 | |
| SCHEMBL17334524 | 0.79 | ALDH1A1 (0.46) | ALDH1A1TDP1HSD17B10TSHRGAA | |
| SCHEMBL14993056 | 0.79 | TDP1 (0.43) | ALDH1A1MAPTFBP1TDP1HSD17B10 | |
| SCHEMBL6935466 | 0.79 | GAA (0.55) | ALDH1A1NPC1MAPTG6PDTDP1 | |
| SCHEMBL729012 | 0.79 | TDP1 (0.40) | ALDH1A1TDP1HSD17B10TSHRGAA | |
| SCHEMBL15216500 | 0.79 | ALDH1A1 (0.48) | ALDH1A1NPC1MAPTFBP1TDP1 | |
| SCHEMBL4712004 | 0.79 | TDP1 (0.43) | ALDH1A1MAPTFBP1TDP1HSD17B10 | |
| SCHEMBL14993055 | 0.79 | TDP1 (0.43) | ALDH1A1MAPTFBP1TDP1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225694-A1 | COMPOSITIONS AND METHODS OF INHIBITING RETINAL DEGENERATION | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225694-A1 | COMPOSITIONS AND METHODS OF INHIBITING RETINAL DEGENERATION | ALDH1A2, PDE6C, NQO1 | ALDH1A1 283/4885NPC1 731/4885MAPT 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.